# AMALEE (NCT03822468)

> Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

No report yet. It can be ordered.

- Drugs tested: ribociclib
- Indication: first-line HR-positive HER2-negative advanced breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03822468
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Breast Cancer
- Interventions: Ribociclib; Anastrozole; Letrozole; Goserelin
- Enrollment: 376
- Primary outcome: Overall Response Rate (ORR)

## Indexed commentary on AMALEE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=amalee-nct03822468